

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Original) A method for the selective enhancement of the expression of a protein in a tumor cell characterized by aberrant Wnt signaling comprising treating said tumor cell with an effective amount of a retinoid.
2. (Canceled)
3. (Currently amended) The method of claim 21, wherein said protein is a cell surface protein.
4. (Currently amended) The method of claim 21 wherein said protein is over-expressed in tumor cells relative to corresponding normal cells.
5. (Currently amended) The method of claim 21 wherein said protein is selected from the group consisting of 4-1BB ligand, ephrin b1, ISLR, autotaxin, and Stra6.
- 6-7. (Canceled)
8. (Original) The method of claim 1 wherein said retinoid is a retinoic acid.
9. (Original) The method of claim 1 wherein said tumor is a human cancer.
10. (Currently amended) The method of claim 9 wherein said human cancer is selected from the group consisting of ovarian cancer, endometrial cancer, Wilms' kidney tumor, colon cancer, or breast cancer, prostate cancer, gastric cancer, lung cancer, hepatocellular cancer, and melanoma.
- 11-66. (Cancelled)

67. (new) A method for the selective enhancement of expression of a protein in a tumor cell characterized by aberrant Wnt signaling comprising treating said tumor cell with an effective amount of a retinoid, wherein said protein is characterized by synergistic enhancement of its expression by a combination of Wnt-1 and said retinoid.

68. (new) The method of claim 67, wherein said protein is a cell surface protein.

69. (new) The method of claim 67, wherein said protein is overexpressed in tumor cells relative to corresponding normal cells.

70. (new) The method of claim 67, wherein said protein is *stra6*.

71. (new) The method of claim 67, wherein said retinoid is a retinoic acid.

72. (new) The method of claim 67, wherein said tumor is a human cancer.

73. (new) The method of claim 72, wherein said human cancer is colon cancer or breast cancer.

74. (new) A method for selective enhancement of the expression of a protein in a tumor cell characterized by aberrant Wnt signaling of a member of Wnt signaling pathway selected from the group consisting of Wnt gene family, APC, catenin, frizzled receptors, dishevelled protein, glycogen synthase kinase-3 $\beta$ , transcription factor TCF/LEF-1, nodal related 3 gene, *Xnr3*, the homeobox genes, *engrailed*, *goosecoid*, *twin (Xtwn)*, *siamois*, *c-myc* and the *WISP* genes, comprising treating said tumor cell with an effective amount of a retinoid.

75. (new) The method of claim 74, wherein the protein is a cell surface protein.

76. (new) The method of claim 74, wherein said protein is overexpressed in tumor cells relative to corresponding normal cells.

- 77. (new) The method of claim 74, wherein the protein is Stra6.
- 78. (new) The method of claim 74, wherein the retinoid is retinoic acid.
- 79. (new) The method of claim 74, wherein the tumor is human cancer.
- 80. (new) The method of claim 79, wherein the human cancer is colon cancer or breast cancer.